{"product_id":"xerispharma-business-model-canvas","title":"Xeris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Xeris’s Business Model Canvas: Ready-to-Use Playbook for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Xeris’s strategic playbook with the full Business Model Canvas—an actionable, section-by-section breakdown revealing value propositions, customer segments, revenue streams, and growth levers; ideal for investors, founders, and consultants seeking a ready-to-use template to benchmark, plan, or present. Download the complete Word and Excel files to transform insights into strategy and scale faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris partners with pharma leaders such as Merck and Amgen to integrate XeriJect for large-molecule delivery, targeting ultra-concentrated biologic formulations that cut injection volume by up to 70% and improve adherence. These deals supplied Xeris with roughly $45M in non-dilutive R\u0026amp;D funding and milestone payments through 2025, validating the platform and opening partner pipelines to wider adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris relies on a network of specialized contract manufacturing organizations (CMOs) to produce commercial products and clinical trial materials for its XeriSol and XeriJect platforms; in 2025 CMOs handled ~100% of manufacturing, supporting annualized capacity to supply projected peak demand of ~50k vials\/month. Maintaining multiple CMO relationships provides technical infrastructure for unique formulations, supply redundancy, and flexibility to scale with market swings in injectable therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Specialty Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris partners with major wholesalers—McKesson, AmerisourceBergen, Cardinal Health—to cover ~80% of U.S. pharmacy reach, linking its manufacturing to hospitals and clinics; wholesale distribution accounted for ~65% of Xeris’s 2024 channel shipments. Specialty pharmacies handle high-touch delivery and monitoring for rare-disease drug Recorlev, supporting adherence and reimbursement workflows that reduce patient discontinuation by ~20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with groups like the American Diabetes Association and rare-disease foundations build trust and awareness, helping Xeris capture unmet needs and refine its value proposition for glucagon and rare endocrine therapies; 2024 patient-advocacy partnerships contributed to a 12% increase in trial recruitment speed and a 7% lift in branded patient-education reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster recruitment: +12% (2024)\u003c\/li\u003e\n\u003cli\u003eEducation reach: +7% (2024)\u003c\/li\u003e\n\u003cli\u003eImproved indication fit: qualitative insights from 5 foundations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris maintains active ties with medical universities and research centers—supporting 12+ investigator-initiated trials and 4 company-sponsored studies since 2022—to secure scientific validation for FDA and EMA approvals and broaden indications in endocrinology and metabolic health.\u003c\/p\u003e\n\u003cp\u003eWorking with academic experts keeps product pipelines current; 2024 co-authored publications numbered 7 and collaborations contributed to a 15% faster time-to-label expansion versus industry peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12+ investigator-initiated trials\u003c\/li\u003e\n\u003cli\u003e4 company-sponsored studies since 2022\u003c\/li\u003e\n\u003cli\u003e7 co-authored papers in 2024\u003c\/li\u003e\n\u003cli\u003e15% faster label expansion vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris nets $45M deals, full manufacturing, 80% pharmacy reach, faster trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris secures strategic pharma deals (Merck, Amgen) that provided ~$45M in non-dilutive funding through 2025, multiple CMOs covering ~100% manufacturing with ~50k vials\/month peak capacity, wholesalers (McKesson, AmerisourceBergen, Cardinal) reaching ~80% U.S. pharmacies and 65% of 2024 shipments, plus advocacy and academic ties boosting recruitment +12% and label expansion speed +15% vs peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003e2024–2025 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma deals\u003c\/td\u003e\n\u003ctd\u003e$45M funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~100% mfg, 50k vials\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~80% reach, 65% shipments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\/academia\u003c\/td\u003e\n\u003ctd\u003eRecruitment +12%, label +15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Xeris that details customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and performance metrics to reflect real-world operations and strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Xeris’s business model with editable cells, condensing strategy into a clean, shareable one-page snapshot ideal for team collaboration, boardrooms, or fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Platform Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe engineering team continuously refines XeriSol and XeriJect to deliver stable, liquid-based subcutaneous and intramuscular therapies, targeting a 30–50% reduction in injection volume versus standard formulations and cutting reconstitution steps to zero; these platforms supported Xeris’s 2024 R\u0026amp;D spend of $62.4M and 6 active IND-enabling programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Product Marketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris spends roughly $75–85M annually on commercialization (2024 run-rate), focusing sales teams and field medical reps on endocrinologists, neurologists and PCPs to grow prescriptions for Gvoke, Keveyis and Recorlev; Gvoke scripts rose ~28% YoY in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating FDA and global regulators is continuous: Xeris spends an estimated $25–40M per NDA lifecycle and files supplements for new indications quarterly as products evolve, while meeting post‑market safety reporting that average 120+ adverse event reconciliations per year.\u003c\/p\u003e\n\u003cp\u003eMaintaining GMP (Good Manufacturing Practices) and healthcare compliance is mandatory to keep licenses; audit readiness costs ~3–5% of revenue and recent 2024 audits led to zero critical observations across 12 inspections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris manages end-to-end movement of temperature-sensitive biopharma with real-time cold-chain monitoring, inventory dashboards, and KPI-driven distribution to cut spoilage; in 2024 Xeris reported \u0026gt;98% on-time shipments and reduced cold-chain losses to under 1.2% across 15 markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time temp monitoring and alerts\u003c\/li\u003e\n\u003cli\u003eInventory thresholds to avoid stockouts\u003c\/li\u003e\n\u003cli\u003eDistribution timelines aligned to regional launches\u003c\/li\u003e\n\u003cli\u003eCold-chain loss \u0026lt;1.2% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe leadership team pursues licensing deals and targeted acquisitions to expand Xeris’ IP and revenue, focusing on partners that can apply the XeriJect platform to their drug candidates; in 2024 Xeris reported licensing revenue of $6.2M and guided for royalty-bearing deals to drive mid-teens royalty margins.\u003c\/p\u003e\n\u003cp\u003eThese efforts prioritize out-licensing and royalty agreements to maximize commercial value, with business development tracking 12 active partnership discussions and aiming to close 2–3 deals annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 licensing revenue: $6.2M\u003c\/li\u003e\n\u003cli\u003eTarget deals\/year: 2–3\u003c\/li\u003e\n\u003cli\u003eActive talks: 12 partners\u003c\/li\u003e\n\u003cli\u003eExpected royalty margins: mid-teens %\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume injection tech drives strong 2024 traction: $62M R\u0026amp;D, $75–85M run-rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngineering advances XeriSol\/XeriJect (30–50% lower injection volume) backed by $62.4M R\u0026amp;D in 2024 and 6 IND programs; commercialization run-rate $75–85M (2024) grew Gvoke scripts ~28% YoY; regulatory lifecycle ~$25–40M per NDA with 120+ safety reconciliations yearly; GMP audits (12 in 2024) had zero critical observations; cold-chain on-time \u0026gt;98%, losses \u0026lt;1.2%; 2024 licensing revenue $6.2M, 12 partner talks, target 2–3 deals\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$62.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial run-rate\u003c\/td\u003e\n\u003ctd\u003e$75–85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke scripts YoY\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND programs\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory cost\/NDA\u003c\/td\u003e\n\u003ctd\u003e$25–40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudits (critical)\u003c\/td\u003e\n\u003ctd\u003e12 (0)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time shipments\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain loss\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing revenue\u003c\/td\u003e\n\u003ctd\u003e$6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive partner talks\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget deals\/yr\u003c\/td\u003e\n\u003ctd\u003e2–3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the actual Xeris Business Model Canvas—not a mockup—and it matches the file you’ll receive after purchase. Upon completing your order, you’ll get this exact, fully editable document in Word and Excel formats, with all sections and content included. No placeholders, no alterations—what you see is the deliverable, ready to present, customize, and implement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749503381881,"sku":"xerispharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/xerispharma-business-model-canvas.png?v=1772214533","url":"https:\/\/matrixbcg.com\/products\/xerispharma-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}